Brokerages Anticipate Allena Pharmaceuticals Inc (NASDAQ:ALNA) to Post -$0.51 Earnings Per Share

Wall Street analysts predict that Allena Pharmaceuticals Inc (NASDAQ:ALNA) will post earnings of ($0.51) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Allena Pharmaceuticals’ earnings. The highest EPS estimate is ($0.40) and the lowest is ($0.57). Allena Pharmaceuticals reported earnings of ($0.46) per share in the same quarter last year, which would indicate a negative year over year growth rate of 10.9%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 5th.

Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that cover Allena Pharmaceuticals.

Allena Pharmaceuticals (NASDAQ:ALNA) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08).

ALNA has been the subject of a number of analyst reports. ValuEngine raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Wedbush restated a “buy” rating and issued a $26.00 price objective on shares of Allena Pharmaceuticals in a research note on Thursday, October 17th. Credit Suisse Group downgraded Allena Pharmaceuticals from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $7.00 to $4.00 in a research note on Friday, November 8th. Zacks Investment Research upgraded Allena Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 12th. Finally, Cowen restated a “buy” rating on shares of Allena Pharmaceuticals in a research note on Thursday, November 14th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Allena Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $17.96.

Large investors have recently made changes to their positions in the business. Paloma Partners Management Co purchased a new position in Allena Pharmaceuticals during the second quarter valued at $212,000. Susquehanna International Group LLP bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $137,000. Jane Street Group LLC bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $116,000. Wedbush Securities Inc. bought a new stake in Allena Pharmaceuticals during the second quarter valued at about $63,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Allena Pharmaceuticals by 17.0% during the second quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock valued at $169,000 after purchasing an additional 6,030 shares during the period. Hedge funds and other institutional investors own 65.57% of the company’s stock.

NASDAQ ALNA traded up $0.20 on Thursday, reaching $1.87. The company had a trading volume of 455,644 shares, compared to its average volume of 149,174. The stock has a market capitalization of $39.19 million, a P/E ratio of -1.07 and a beta of 2.02. The company’s fifty day moving average is $4.17 and its 200 day moving average is $4.44. Allena Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $10.66. The company has a quick ratio of 3.96, a current ratio of 3.96 and a debt-to-equity ratio of 0.28.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.

Read More: Why is total return important?

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allena Pharmaceuticals (NASDAQ:ALNA)

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.